Stem cell therapies advance in Parkinson’s disease and beyond
June 4, 2025
0
Comments
12 Views
Read in 1 Minute
During the height of New York City’s COVID-19 lockdown, a small group of people with Parkinson’s disease arrived at Memorial Sloan Kettering Cancer Center for an experimental neurosurgical procedure: the implantation of dopamine-producing neurons grown from human embryonic stem cells. Now, the researchers behind the trial have published results from that phase 1 study, showing that the transplanted cells survived, released dopamine and were well tolerated1. Some participants even experienced visible reductions in tremors.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41591-025-00036-6
The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.
